| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2014PLoSO...9k5940W |
| P356 | DOI | 10.1371/JOURNAL.PONE.0115940 |
| P8608 | Fatcat ID | release_upcw23crhrh3fpdzouolpbifym |
| P932 | PMC publication ID | 4275259 |
| P698 | PubMed publication ID | 25536060 |
| P5875 | ResearchGate publication ID | 270001252 |
| P50 | author | Sascha Flohé | Q46920067 |
| P2093 | author name string | Martin Scholz | |
| Joachim Windolf | |||
| Ceylan D Windolf | |||
| Tim Lögters | |||
| P2860 | cites work | A new intra-arterial delivery platform for pro-arteriogenic compounds to stimulate collateral artery growth via transforming growth factor-beta1 release. | Q50949576 |
| Biomechanical and allergological characteristics of a biodegradable poly(D,L-lactic acid) coating for orthopaedic implants. | Q51400098 | ||
| Changing the release kinetics of gentamicin from poly(D,L-lactide) implant coatings using only one polymer. | Q52896788 | ||
| Surface-associated protein from Staphylococcus aureus stimulates osteoclastogenesis: possible role in S. aureus-induced bone pathology. | Q54115720 | ||
| Gentamycin delivered from a PDLLA coating of metallic implants | Q56992720 | ||
| Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model | Q81234087 | ||
| Concise review of mechanisms of bacterial adhesion to biomaterial surfaces | Q93911932 | ||
| Lysostaphin Disrupts Staphylococcus aureus and Staphylococcus epidermidis Biofilms on Artificial Surfaces | Q24650674 | ||
| Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model | Q24682172 | ||
| Crystal structure of the antimicrobial peptidase lysostaphin fromStaphylococcus simulans | Q27684730 | ||
| Bacterial biofilms: a common cause of persistent infections | Q27861033 | ||
| Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit | Q28143682 | ||
| LYSOSTAPHIN: A NEW BACTERIOLYTIC AGENT FOR THE STAPHYLOCOCCUS | Q28156580 | ||
| Antibiotic resistance of bacteria in biofilms | Q28207706 | ||
| Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis | Q28379547 | ||
| The future of biologic coatings for orthopaedic implants | Q28394906 | ||
| Antibiotic activity against small-colony variants of Staphylococcus aureus: review of in vitro, animal and clinical data | Q30597709 | ||
| Biodegradable poly(D,L-lactide) coating of implants for continuous release of growth factors | Q31926776 | ||
| Lysostaphin as a potential therapeutic agent for staphylococcal biofilm eradication | Q33232677 | ||
| Staphylococcus aureus adhesion to bone matrix and bone-associated biomaterials | Q33607466 | ||
| Quorum sensing in Staphylococcus infections | Q33630510 | ||
| Lysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications | Q33664443 | ||
| Staphylococcus and biofilms | Q34600780 | ||
| The relative contributions of physical structure and cell density to the antibiotic susceptibility of bacteria in biofilms | Q36018792 | ||
| Biofilm in implant infections: its production and regulation. | Q36341333 | ||
| The significance of infection related to orthopedic devices and issues of antibiotic resistance | Q36346573 | ||
| ica and beyond: biofilm mechanisms and regulation in Staphylococcus epidermidis and Staphylococcus aureus | Q36785892 | ||
| Lysostaphin: an antistaphylococcal agent | Q37209589 | ||
| Antibiotic resistance of bacterial biofilms | Q37690946 | ||
| Emerging pathogenetic mechanisms of the implant-related osteomyelitis by Staphylococcus aureus | Q37957607 | ||
| Biofilm formation in Staphylococcus implant infections. A review of molecular mechanisms and implications for biofilm-resistant materials | Q38018423 | ||
| A review of the biomaterials technologies for infection-resistant surfaces | Q38129576 | ||
| Recent lessons for the management of bone and joint infections | Q38152064 | ||
| The immunomodulatory activity of Staphylococcus aureus products derived from biofilm and planktonic cultures. | Q42131269 | ||
| Inhibition of the Activity of Both Domains of Lysostaphin through Peptidoglycan Modification by the Lysostaphin Immunity Protein | Q42411103 | ||
| Bap, a Staphylococcus aureus surface protein involved in biofilm formation | Q42737702 | ||
| Efficacy of a norvancomycin-loaded, PDLLA-coated plate in preventing early infection of rabbit tibia fracture | Q43052929 | ||
| Microbiology of the infected knee arthroplasty: report from the Swedish Knee Arthroplasty Register on 426 surgically revised cases | Q43239635 | ||
| Molecular Properties of Lysostaphin, a Bacteriolytic Agent Specific for Staphylococcus aureus | Q43462980 | ||
| Local application of zoledronic acid incorporated in a poly(D,L-lactide)-coated implant accelerates fracture healing in rats | Q43677840 | ||
| Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus endophthalmitis in the rabbit | Q43755005 | ||
| Studies with lysotaphin. II. Lysostaphin sensitivity of 230 strains of Staph. aureus of animal origin | Q44228104 | ||
| Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit. | Q44231124 | ||
| Implant-associated posttraumatic osteomyelitis: collateral damage by local host defense? | Q44997805 | ||
| Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice. | Q46034505 | ||
| Post-traumatic osteomyelitis: analysis of inflammatory cells recruited into the site of infection | Q47377003 | ||
| Implant-associated localized osteitis in murine femur fracture by biofilm forming Staphylococcus aureus: a novel experimental model | Q47955099 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| P304 | page(s) | e115940 | |
| P577 | publication date | 2014-12-23 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Lysostaphin-coated titan-implants preventing localized osteitis by Staphylococcus aureus in a mouse model | |
| P478 | volume | 9 |
| Q61658129 | A New Bioactive Compound From the Marine Sponge-Derived sp. SBT348 Inhibits Staphylococcal Growth and Biofilm Formation |
| Q35846513 | A new animal model for delayed osseous union secondary to osteitis |
| Q95643042 | A systematic review on current osteosynthesis-associated infection animal fracture models |
| Q40796792 | An in vitro study on disinfection of titanium surfaces |
| Q58768791 | Coatings as the useful drug delivery system for the prevention of implant-related infections |
| Q64095049 | Effect of antibiotic infused calcium sulfate/hydroxyapatite (CAS/HA) insets on implant-associated osteitis in a femur fracture model in mice |
| Q48149676 | Effect of hyperbaric oxygen therapy (HBO) on implant-associated osteitis in a femur fracture model in mice. |
| Q54212204 | Hydrogel delivery of lysostaphin eliminates orthopedic implant infection by Staphylococcus aureus and supports fracture healing. |
| Q92070305 | Impact of Bacterial Infections on Osteogenesis: Evidence From In Vivo Studies |
| Q90473947 | Nonconventional Therapeutics against Staphylococcus aureus |
| Q38844138 | Osteogenic differentiation and proliferation of bone marrow-derived mesenchymal stromal cells on PDLLA + BMP-2-coated titanium alloy surfaces |
| Q37482155 | Prevention and treatment of Staphylococcus aureus biofilms |
| Q26766421 | Staphylococcal Superantigens Spark Host-Mediated Danger Signals |
| Q40427118 | Thermally triggered release of the bacteriophage endolysin CHAPK and the bacteriocin lysostaphin for the control of methicillin resistant Staphylococcus aureus (MRSA) |
Search more.